Can You Get an Allergy Shot? Medical Eligibility, Contraindications & Next Steps

Absolute contraindications that prevent allergy shot initiation include: severe or uncontrolled asthma with FEV1 below 70% predicted or recent asthma-related emergency room visit, concurrent non-cardioselective beta-blocker therapy (which blocks epinephrine effectiveness needed to treat anaphylaxis), severe immunodeficiency disorders, and inability to communicate symptoms of systemic reaction to the medical team. Pregnancy is a contraindication for initiating new immunotherapy or increasing doses, though maintenance can be continued in patients already established on a stable dose. Malignant neoplastic disease and active autoimmune disease requiring immunosuppression are also relative or absolute contraindications depending on the clinical judgment of the treating allergist. These restrictions are not arbitrary — each reflects a specific safety or efficacy concern. Patients with relative contraindications (mild asthma, ACE inhibitor use, older age with comorbidities) can often receive shots with appropriate monitoring.

Yes — confirmed IgE-mediated sensitization is a prerequisite for allergy shots, not an optional step. Allergy shots work by gradually desensitizing your immune system to specific allergens — your allergist cannot design an appropriate extract formula without knowing which allergens you actually react to. Documentation requires either positive skin prick testing (the in-office scratch test that allergists administer) or positive serum-specific IgE blood testing (such as ImmunoCAP). The testing results must correlate with your clinical symptoms — sensitization without relevant symptom history does not by itself indicate a need for immunotherapy. The AAAAI diagnostic criteria require both documented IgE sensitization and clinically relevant symptoms to establish the indication for immunotherapy. Patients who proceed to an allergist consultation without prior testing can have skin testing performed during the same appointment in most allergy practices.

Yes, allergy shots can be given to patients with asthma, but asthma must be adequately controlled before and during treatment. The clinical threshold is FEV1 at or above 70% predicted — meaning your lung function meets a minimum control standard. Patients with well-controlled asthma on appropriate maintenance medication (inhaled corticosteroids, long-acting bronchodilators) are eligible for immunotherapy and often benefit significantly, since allergic asthma and allergic rhinitis share underlying IgE mechanisms. In fact, addressing the allergic drivers of asthma through immunotherapy can meaningfully reduce asthma exacerbations and medication needs over time. Patients with severe or uncontrolled asthma — FEV1 below 70%, recent ER visits for asthma, current wheezing — must first stabilize asthma control before starting shots. Each injection visit requires assessment of current asthma status, and allergists may postpone a dose if your breathing is suboptimal on a given visit.

Pregnant women cannot initiate new allergy shot treatment or receive dose increases during pregnancy. AAAAI practice parameters are clear: if you are not already established on a stable maintenance dose, pregnancy is a contraindication to starting immunotherapy. The concern is systemic anaphylaxis — if a severe reaction occurs, the epinephrine treatment necessary to manage it could affect uterine blood flow and fetal wellbeing. However, if you are already in the maintenance phase of allergy shots and become pregnant, you can generally continue at your current stable dose. Most allergists recommend continuing rather than stopping, as the risk of a reaction at a well-tolerated maintenance dose is low and the ongoing benefit of treatment has value. Dose escalation during pregnancy is not recommended regardless of phase. If you are planning pregnancy, discuss the timing of your immunotherapy initiation with your allergist to optimize your position — ideally reaching stable maintenance before conception.

Yes — clinical guidelines recommend that patients demonstrate inadequate response to at least one season of optimized pharmacotherapy before proceeding to immunotherapy. Optimized pharmacotherapy means consistently using a daily second-generation antihistamine (cetirizine, loratadine, or fexofenadine) plus a daily intranasal corticosteroid (fluticasone, budesonide, or mometasone) throughout the allergy season. If this regimen provides excellent symptom control with minimal impact on quality of life, immunotherapy may not add meaningful benefit. The ARIA stepped care framework (Brozek et al., JACI, 2017) positions immunotherapy at step 4, after steps 1-3 (allergen avoidance, antihistamines, nasal steroids) have been tried. One important exception: patients who are not allergic medication failures but want the disease-modification benefit of immunotherapy — particularly parents of young children seeking to prevent the allergic march — may be appropriate candidates even without strict pharmacotherapy failure.

Yes — there is no upper age limit for allergy immunotherapy. A study by Bozek et al. (Annals of Allergy, Asthma and Immunology, 2016) demonstrated comparable efficacy and safety in patients aged 65 and older compared to younger adults. Elderly patients can both initiate and benefit from immunotherapy, though candidacy assessment must account for age-related comorbidities. Key considerations for elderly patients: beta-blocker use for cardiovascular conditions (which is an absolute contraindication), cardiovascular disease that increases systemic reaction risk, cognitive impairment that may affect the ability to communicate reaction symptoms, and the logistical challenge of weekly visits during build-up. None of these are categorical disqualifiers — they require individualized risk-benefit assessment by the allergist. Elderly patients in generally good health without beta-blockers or severe cardiovascular disease are often excellent immunotherapy candidates who report significant quality of life improvement.

The generally accepted minimum age for allergy shots is 5 years, based on functional criteria rather than biological age alone. At age 5, most children can reliably communicate early symptoms of a systemic reaction ('my throat feels funny,' 'I feel dizzy') and cooperate with the injection procedure and 30-minute observation period. These communication and cooperation abilities — not a specific developmental milestone — determine readiness. Some experienced pediatric allergists initiate immunotherapy in select children aged 3-4 on a case-by-case basis when symptoms are severe and the child demonstrates adequate communication ability and parental supervision is comprehensive. The age 5 guideline is a practical consensus threshold, not an absolute biological cutoff. Early treatment in eligible children is encouraged because childhood immunotherapy has the strongest disease-modification evidence — the PAT study showed 50% asthma prevention in children aged 6-14 who received immunotherapy.